Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES |
|---|---|
| Recipient Organization | Boston Children'S Hospital |
| Country | United States |
| Start Date | Mar 10, 2022 |
| End Date | Feb 28, 2027 |
| Duration | 1,816 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10796876 |
PROJECT SUMMARY: IDEAL Administrative Core Our overall proposal will investigate immune development in early life (IDEAL) to identify IDEAL endotypes that correspond to key clinical outcomes in childhood, including vaccine response, respiratory infectious disease and asthma. We will accomplish this goal through three distinct yet integrated studies that follow
complementary approaches via cutting-edge in silico (project 1, PR1), epigenetic (PR2), and in vitro (PR3) research projects. Given the scientific scope, complexity, and geographic range of the proposed work, the study IDEAL Administrative Core (AC) will be crucial to optimize the quality and impact of the proposed
studies and to ensure timely provision of projected deliverables. The goal of the IDEAL-AC is to institute streamlined processes which facilitate productive interactions among investigators from each IDEAL Project and Core. We will achieve this goal by pursuing the following Specific Aims (SAs): SA1. Provide infrastructure for administrative leadership aimed at building an interactive and
collaborative working team resulting in maximal project synergy. SA2. Facilitate and promote communication and interactions amongst the Project and Core Leads by conducting regular teleconferences/face-to-face meetings, annual meetings, as well as seminars/symposia focused on the IDEAL project. SA3. Manage and optimize communication within our IDEAL team and between our team, the
other NIH supported IDEAL teams and the IDEAL Steering Committee. SA4. Resolve potential conflicts that might arise within and outside of our IDEAL project by implementing recommendations of the Conflicts Resolution Group (CRG). SA5. Provide fiscal, regulatory and scientific oversight, review and consolidate yearly progress
reports sent to the NIH. SA6. Protect intellectual property rights of our investigators and execute material transfer agreements. SA7. Implement the data management/sharing plan among investigators within and outside of our IDEAL team. Overall, the IDEAL AC will ensure appropriate stewardship of NIH funds and maintain adherence to
project timelines, all with the goal to optimize and amplify the scientific impact of the proposed studies.
Boston Children'S Hospital
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant